Microbiological aspects and antibiotic therapy of diabetic foot infections;Mikrobiologische aspekte und rationelle antibiotische therapie des diabetischen fußsyndroms

Medizinische Klinik

Volumn 98, Issue 5, 2003, Pages 259-265

  Ambrosch, Andreas ^a   Lehnert, Hendrik ^b   Lobmann, Ralf ^b  

^a StJoseph Hospital Bremerhaven   (Germany)

^b OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

Antibiotic therapy; Diabetic foot infection; Staphylococci and biofilm

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BACTERIAL POLYSACCHARIDE; BETA LACTAM ANTIBIOTIC; CARBAPENEM; CEFAZOLIN; CEFOTAXIME; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CHLORHEXIDINE; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; CLINDAMYCIN; FLUCLOXACILLIN; GENTAMICIN; LINCOSAMIDE; NEOMYCIN; OFLOXACIN; PENICILLIN DERIVATIVE; POLYMYXIN B; PSEUDOMONIC ACID; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULFADIAZINE SILVER; SULTAMICILLIN; TEICOPLANIN; UNINDEXED DRUG;

ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; BACTERIUM ADHERENCE; BIOFILM; BONE INFECTION; COAGULASE NEGATIVE STAPHYLOCOCCUS; DIABETES CONTROL; DIABETIC FOOT; DISEASE SEVERITY; DRUG EFFICACY; EPIDEMIOLOGICAL DATA; HUMAN; IMMUNE RESPONSE; INFECTION RISK; PATHOGENESIS; REVIEW; SKIN INFECTION; STAPHYLOCOCCUS AUREUS; TREATMENT OUTCOME; WOUND CARE;

ANTI-BACTERIAL AGENTS; DIABETIC FOOT; HUMANS; MICROBIAL SENSITIVITY TESTS; OSTEOMYELITIS; SOFT TISSUE INFECTIONS; STAPHYLOCOCCAL INFECTIONS; TREATMENT OUTCOME;

BACTERIA (MICROORGANISMS); STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS;

EID: 0037950630     PISSN: 07235003     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00063-003-1254-0     Document Type: Review

References (77)

1. New JP, McDowell D, Burns E, Young RJ. Problem of amputations in patients with newly diagnosed diabetes mellitus. Diabet Med 1998;15:760-4.
2. McGill M, Collins P, Bolton T, Yue DK. Management of neuropathic ulceration. J Wound Care 1996;5:52-4.
3. Apolquist J, Larsson J, Agardh CD. Long-term prognosis for diabetic patients with foot ulcers. J Intern Med 1993;233:485-91.
4. Williams DR. Hospital admissions of diabetic patients. Information from hospital activity analysis. Diabet Med 1985;2:27-32.
5. Armstrong DG, Lavery LA, Quebedeaux TL, Walker SC. Surgical morbidity and the risk of amputation due to infected puncture wounds in diabetics versus nondiabetic adults. J Am Podiatr Med Assoc 1997;87:321-6.
6. Boyko EJ, Ahroni JH, Smith DG, Davignon D. Increased mortality associated with diabetic foot ulcer. Diabet Med 1996;11:967-72.
7. DeFronzo RA, Reasner C. The diabetes control and complications trial study, implications for the diabetic foot. J Foot Ankle Surg 1994;33:551-6.
8. Liebl A, Neiss A, Spannheimer A, Reitberger U, Wagner T, Gortz A. Costs of type 2 Diabetes in Germany. Results of the CODE-2 study. Dtsch Med Wochenschr 2001;126:585-9.
9. Tennvall GR, Apelqvist J, Eneroth M. Cost of deep infections in patients with diabetes mellitus. Pharmacoeconomics 2000;18:225-38.
10. Fryberg RG. Diabetic foot ulcers. Current concepts. J Foot Ankle Surg 1998;37:440-6.
11. Holstein PE, Sorensen S. Limb salvage experience in a multidisciplinary diabetic foot unit. Diabetes Care 1999;22:B97-103.
12. The Saint Vincent Declaration. Diabetes Care and Research Group in Europe. Diabet Med 1990;7:360.
13. Trautner C, Haastert B, Giani G, Berger M. Incidence of lower limb amputations and diabetes. Diabetes Care 1996;9:1006-9.
14. Standl E, Mendler G, Zimmermann R, Stiegler H. Zur Amputationshäufigkeit von Diabetikern in Deutschland. Diabetes 1996;5:29-32.
15. Trautner C Haastert B, Spraul M, Giani B, Berger M. Unchanged incidence of lower-imb amputations in a German setting 1990-1998. Diabetes Care 2001;24: 855-9.
16. Simeone LR, Veves A. Screening techniques to identify the diabetic patient at risk of ulceration. J Am Podiatr Med Assoc 1997;87:313-7.
17. Caputo GM, Cavanagh PR, Ulbrecht JS, Gibbons GW, Karchmer AW. Assessment and management of foot disease in patients with diabetes. N Engl J Med 1994;331:854-60.
18. Mueller MJ. Therapeutic footwear helps protect the diabetic foot. J Am Podiatr Med Assoc 1997;87: 360-4.
19. Spraul M, Hrsg. Internationaler Konsensus über den Diabetischen Fuß. Mainz: Kirchheim, 1999.
20. Boyko EJ, Lipsky BA. Infection and diabetes mellitus. In: Harris MI, ed. Diabetes in America. NIH Publications No 95-1468. Bethesda: National Institutes of Health, 1995:485-99.
21. Pozzilli, P, Leslie RDG. Infections and diabetes. Mechanisms and prospects of prevention. Diabet Med 1995;11:935-41.
22. Patti JM, Boles JO, Höök M. Identification and biochemical characterization of the ligand binding domain ofcollagen adhesin of Staphylococcus aureus. Biochemistry 1993;32:11428-35.
23. Greene C, Vaudaux PE, Francois P, Proctor RA, McDevitt D, Foster TJ. A low-fibronectin-binding mutant of Staphylococcus aureus 879K4S has Tn918 inserted into its single fnb gene. Microbiology 1996;142:2153-60.
24. Marhoffer W, Stein M, Maeser E, Federlin K. Impairment of polymorphonuclear leukocyte function and metabolic control of diabetes. Dabetes Care 1992;15:256-60.
25. Balasubrmanyam M, Premanand C, Mohan V. The lymphocyte as a cellular model to study insights into the pathophysiology of diabetes and its complications. Ann N Y Acad Sci 2002;958:399-402.
26. Orie NN, Zidek W, Tepel M. Reactive oxygen species in essential hypertension and non-insu]in-dependent diabetes mellitus. Am J Hypertens 1999;12: 1169-74.
27. Moutschen MP, Scheen AJ, Lefebre PJ. Impaired immune responses in diabetes mellitus. Analysis of the factors and mechanisms involved. Relevance to the increased susceptibility of diabetic patients to specific infections. Diabete Metab 1992;18:187-201.
28. Bouter KP, Meyling FH, Hoekstra JB, Masurel N, Erkelens DW, Diepersloot RJ. Influence of blood glucose levels on peripheral lymphocytes in patients with diabetes mellitus. Diabetes Res 1992;19:77-80.
29. Akiyama H, Huh WK, Yamasaki O, Oono T, Iwatsuki K. Confocal laser scanning microscopic observation of glycocalyx production by Staphylococcus aureus in mouse skin: does S. aureus generally produce a biofilm on damaged skin? Br J Dermatol 2002;147: 879-85.
30. Ludwicka A, Jansen B, Wadström Pulverer G. Attachment of staphylococci to various synthetic polymers. Zentralbl Bakteriol Hyg 1984;256:479-89.
31. Toledo-Arana A, Valle J, Solano C, Arrizubieta MJ, Cucarella C, Lamata M, Amorena B, Leiva J, Penades JP, Lasa I. The enterococcal surface protein esp is involved in Enterococcus faecalis biofilm formation. Appl Environ Microbiol 2001;67:4338-45.
32. Cucarella C, Solano C, Valle J, Amorena I, Lasa I, Penades JR. Bap, a Staphyloccus aureus surface protein involved in biofilm formation. J Bacteriol 2001;183: 2888-96.
33. Espinosa-Urgel M, Salido A, Ramos JL. Genetic analysis of functions involved in adhesion of Pseudomonas putrida to seeds. J Bacteriol 2000;182: 2363-9.
34. Bergamini TM, Corpus RA, Hoeg KL, Brittian KR, Peyton JC, Cheadle WG. Immune regulation of bacterial biofilm graft infection. ASAIO J 1994;40: 219-26.
35. Dasgupta MK. Biofilm causes decreased production of interferon-gamma. J Am Soc Nephrol 1996;7: 877-82.
36. Steinberg D, Poran S, Shapira L. The effect of extracellular polysaccharides from Streptococcus mutans on the bactericidal activity of human neutrophils. Arch Oral Biol 1999;44:437-44.
37. Yasuda H, Ajiki Y, Aoyama J, Yokota T. Interaction between human polymorphonuclear leucocytes and bacteria released from in-vitro bacterial biofilm models. J Med Microbiol 1994;41:359-67.
38. Roggenkamp A, Sing A, Hornef M, Brunner U, Autenrieth IB, Heesemann J. Chronic prosthetic hip infection caused by a small-colony variant of Escherichia coli. J Clin Microbiol 1998;36:2530-4.
39. Eiff C von, Heilmann C, Proctor RA, Woltz C, Peters G, Gotz F. A site-directed Staphylococcus aureus hemB mutant is a small-colony variant which persists intracellularly. J Bacteriol 1997;179:4706-12.
40. Eiff C von, Proctor RA, Peters G. Staphylococcus aureus small colony variants. Formation and clinical impact. Int J Clin Pract Suppl 2000;115:44-9.
41. Eiff C von, Lindner N, Proctor RA, Winkelmann W, Peters G. Development of gentamicin-resistant small colony variants of S. aureus after implantation of gentamicin chains in osteomyelitis as a possible cause of recurrence. Z Orthop Ihre Grenzgeb 1998; 136:268-71.
42. Proctor RA, Peters G. Small colony variants in staphylococcal infections. Diagnostic and therapeutic implications. Clin Infect Dis 1998;27:419-22.
43. Meghji S, Crean SJ, Hill PA, Sheikh M, Nair SP, Heron K, Henderson B, Mawer EB, Harris M. Surface associated protein from Staphylococcus aureus stimulates osteoclasteogenesis. Possible role in S. aureus-induced bone pathology. Br J Rheumatol 1998;37:1095-101.
44. Nair SP, Meghji S, Wilson M, Reddi K, White P, Henderson B. Bacterial induced bone destruction, mechanisms and misconceptions. Infect Immun 1996;64:2371-80.
45. Grayston ML, Gibbson GW, Balogh K. Probing to bone in infected pedal ulcers. A clinical sign of underlying osteomyelitis in diabetic patients. JAMA 1995;273:721-3.
46. Craig JG, Amin MB, Wu K, Eyler WR, van Holsbeeck MT, Bouffard JA, Shirazi K. Osteomyelitis of the diabetic foot. MR imaging - pathologic correlation. Radiology 1997;203:849-55.
47. Morrison WB, Schweitzer ME, Batte WG, Radack DP, Russel KM. Osteomyelitis of the foot. Relative importance of primary and secondary MR imaging signs. Radiology 1998;207:625-32.
48. Howard CB, Einhom M, Dagan P, Yagupski P, Porat S. Fine-needle biopsy to diagnose osteomyelitis. J Bone Joint Surg Br 1994;76:311-4.
49. Mackowiak PA, Jones SK, Smith JW. Diagnostic value of sinus tract cultures in chronic osteomyelitis. JAMA 1978;239:2772-8.
50. Lipsky BA. Osteomyelitis of the foot in diabetic patients. Clin Infect Dis 1997;25:1318-26.
51. Grayston ML, Gibbons GW, Habershaw GM, Freeman D, Pomposelli F, Rosenblum B. Use of ampicillin/sulbactam versus imipenem/cilastin in the treatment of limb-threatening foot infections in diabetic patients. Clin Infect Dis 1994;18:683-93.
52. Blume PA, Dey HM, Daley LJ. Diagnosis of pedal osteomyelitis with Tc-99m HMPAO labeled leukocytes. J Foot Ankle Surg 1997;36:120-6.
53. Seabrook GR, Edmiston CE, Schmitt DD. Comparison of serum and tissue antibiotic levels in diabetic-related foot infections. Surge 1991;110:671-7.
54. El-Sherif El-Sarkey M. Local intravenous therapy in chronic and inflammatory disorders of the foot. Int Surg 1997;82:175-82.
55. Marangos MN, Skoutelis AT, Nightingale CH. Absorption of ciprofloxacin in patients with diabetic gastroparesis. Antimicrob Agents Chemother 1995; 39:2161-3.
56. Duckworth C, Fisher JF, Carter SA. Tissue penetration of clindamycin in diabetic foot infections. J Antimicrob Chemother 1993;31:581-3.
57. Kuck EM, Bouter KP, Hoekstra JBL. Issue concentrations after a single-dose, orally administered ofloxacin in patients with diabetic foot infections. Foot Ankle Int 1998;19:38-40.
58. Lipsky BA, MacDonald D, Litka PA. Treatment of infected diabetic foot ulcers. Topical MSI-78 vs oral ofloxacin. Diabetologia 1997;40:Suppl 1:482.
59. Peterson L, Lissack L, Canter K, Fasching C, Clabots C, Gerding D. Therapy of lower extremity infections with ciprofloxacin in patients with diabetes mellitus, peripheral vascular disease or both. Am J Med 1989; 86:801-8.
60. Gentry L, Rodriguez-Gomez G. Ofloxacin versus parenteral therapy for chronic osteomyelitis. Antimicrob Agents Chemother 1991;35:538-41.
61. Diamantopoulos E, Haritos D, Yfandi D, Gngoriadou M, Margariti G, Paniara O. Management and outcome of severe diabetic foot infections. Endocrinol Diabetes 1998;106:346-52.
62. Lipsky B, Baker P, Landon G, Fernau R. Antibiotic therapy for diabetic foot infections. Comparison of two parenteral-to-oral regimens. Clin Infect Dis 1997;24:643-8.
63. Kanellakopoulou K, Giamarellou H. Clinical experience with parenteral and oral ofloxacin in severe infections. Scand J Infect Dis 1990;68:64-9.
64. Eron L, Gentry L. Oral ofloxacin for infections caused by bacteria resistant to oral antimicrobial agents. Diagn Microbiol Infect Dis 1992;15:435-9.
65. Galanakis N, Giamarellou H, Moussas T, Dounis E. Chronic osteomyelitis caused by multi-resistant gram-negative bacteria. Evaluation oftreatment with newer quinolones after prolonged follow-up. J Antimicrob Chemother 1997;39:241-6.
66. Akova M, Ozcebe O, Gullu I, Unai S, Gur D, Akalin S. Efficacy of sulbactam-ampicillin for the treatment ofsevere diabetic foot infections. J Chemother 1996; 8:284-9.
67. Dorigo B, Cameli A, Trapani M, Raspanti D, Torri M, Mosconi G. Efficacy of femoral intra-arterial administration of teicoplanin in gram-positive diabetic foot infections. Angiology 1995;46:1115-22.
68. Tan JS, Wisdhnow RM, Talan D, and the Piperacillin/Tazobactam Skin and Skin Structure Study Group. Treatment of hospitalized patients with complicated skin and skin structure infections. Double-blind, randomized multicenter study of piperacillin - tazobactam vs ticarcillin - clavulanate. Antimicrob Agents Chemother 1993;37:1580-6.
69. Lipsky BA, Pecoraro RE, Larson SA, Ahroni JH. Outpatient management of uncomplicated lower-extremitiy infections in diabetic patients. Arch Intern Med 1990;150:790-7.
70. Tan JS, Friedman NM, Hazelton-Miller C. Can aggressive treatment of diabetic foot infections reduce the need for above-ankle amputation? Clin Infect Dis 1996;23:286-91.
71. Eneroth M, Apelqvist J, Stenstrom A. Clinical characteristics and outcome in 223 diabetic patients with deep foot infections. Foot Ankle Int 1997;18:716-22.
72. Lipsky MD. A current approach to diabetic foot infections. Curr Infect Dis Rep 1999;1:253-60.
73. Ge Y, MacDonald D, Henry MM, Hait HI, Nelson KA, Lipsky BA, Zasloff MA, Holroyd KJ. In-vitro susceptibility to pexiganan of bacteria isolated from diabetic foot ulcers. Diagn Microbiol Infect Dis 1999;35:45-53.
74. Nakamoto DA, Rosenfield ML, Haaga JR, Merritt K, Sachs PB, Graham RC, Rowland DY. In vivo treatment of infected prosthetic graft material with urokinase. An animal model. J Vasc Interv Radiol 1994;5:549-52.
75. Nemotot K, Hirota K, Ono T, Murakami K, Murakami K, Nagao D, Miyake Y. Effect of varidase (streptokinase) on biofilm formed by Staphylococcus aureus. Chemotherapy 2000;46:111-5.
76. Hentzer M, Riedel K, Rasmussen TB, Heydom A, Andersen JB, Parsek MR, Rice SA, Eberl L, Molin S, Holby N, Kjelleberg S, Givskov M. Inhibition of quorum sensing in Pseudomonas aeruginosa biofilm bactseria by halogenated furanone compound. Microbiology 2002;148:87-102.
77. Ren D, Sims JJ, Wood TK. Inhibition of biofilm formation and swarming of Escherichia coli by (5Z)-4-bromo-5-(bromomethylene)-3-buthyl-2(5H) furanone. Environ Microbiol 2001;3:731-6.